drugset / Trial / NCT05620134
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.
Timeline
- Start
- 2022-10-17
- Primary completion
- 2025-10-17
- Completion
- 2026-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JK08 | Protein / enzyme biologic | — | Subcutaneous |
| Background | Lenvatinib | Small molecule | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |
Indications
clear cell renal carcinoma
colorectal adenocarcinoma
gastric adenocarcinoma
gastroesophageal cancer
head and neck squamous cell carcinoma
hepatocellular carcinoma
malignant epithelial tumor of ovary
melanoma
metastatic malignant neoplasm
non-small cell lung carcinoma
pancreatic adenocarcinoma
papillary renal cell carcinoma
skin squamous cell carcinoma
small cell lung carcinoma
thyroid cancer
triple-negative breast carcinoma
urothelial carcinoma